371.jpg)
India's first nasal COVID-19 vaccine, developed by Bharat Biotech, has been given the regulatory approval for conducting phase 2/3 clinical trials, the government said on Friday. "This is the first-of-its-kind COVID-19 jab to undergo human clinical trials in India," said a government release. Phase 1 clinical trial has been completed in the 18-60 years age group, it added.
India's first nasal COVID-19 vaccine, developed by Bharat Biotech, has been given the regulatory approval for conducting phase 2/3 clinical trials, the government said on Friday. "This is the first-of-its-kind COVID-19 jab to undergo human clinical trials in India," said a government release. Phase 1 clinical trial has been completed in the 18-60 years age group, it added.
